

# Radiotherapy in Ovarian Clear Cell Cancer

Mary McCormack - NCRI  
GCIG Lisbon 2016

# Ovarian Clear Cell Cancer


- Rare & distinct subtype of EOC 5-25% of all cases
- 47-80% stage I/II at diagnosis cf other EOC
- Most OCCC studies are retrospective /single institution and from Japan
- Lack of consensus on adjuvant treatment
- Relapsed disease refractory to chemo
- Some reports suggesting RT reduces relapse

# Results of GCIIG Survey

- NCRI and NCIC circulated a survey of 3 different trial designs (Phase II /III) for GCIIG member groups consideration
- Responses received from 15 groups (we have only used 1 response per group)

# ROCC Agreed Trial Design

Preference for upfront randomisation (rather than after 3 cycles of chemo) and Phase II/III design



# ROCC Summary Eligibility

- Women diagnosed with either pure clear cell or mixed endometrioid and clear cell ovarian cancer FIGO stage Ic2/3 and stage II using an agreed pathology manual and confirmed on retrospective central pathology review
- Patients fit to receive both chemotherapy and radiotherapy (ECOG PS = 0/1)
- Full surgical staging to include pelvic and para-aortic lymph nodes

# ROCC Trial Design

- Median survival for control arm of 5 years
- Aim to detect an improvement to 8 years
- HR = 0.625
- Power = 80%
- Two sided 5% significance level
- N = ~350
- 5 years of accrual and 3 years of follow-up

# ROCC Current Status

- Joint Collaboration with Anna Tinker and Canadian colleagues
- Outline Application submitted to Cancer Research UK September 2016
- If invited for Full Application – committee review March 2017
- Translational component to identify molecular markers – pending application